- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02831179
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors
Study Overview
Status
Conditions
- Merkel Cell Carcinoma
- Neuroendocrine Neoplasm
- Metastatic Carcinoid Tumor
- Functional Pancreatic Neuroendocrine Tumor
- Malignant Somatostatinoma
- Metastatic Adrenal Gland Pheochromocytoma
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type 2A
- Multiple Endocrine Neoplasia Type 2B
- Non-Functional Pancreatic Neuroendocrine Tumor
- Pancreatic Glucagonoma
- Pancreatic Insulinoma
- Recurrent Adrenal Cortex Carcinoma
- Recurrent Adrenal Gland Pheochromocytoma
- Recurrent Merkel Cell Carcinoma
- Somatostatin-Producing Neuroendocrine Tumor
- Stage III Adrenal Cortex Carcinoma
- Stage III Thyroid Gland Medullary Carcinoma
- Stage IIIA Merkel Cell Carcinoma
- Stage IIIB Merkel Cell Carcinoma
- Stage IV Adrenal Cortex Carcinoma
- Stage IV Merkel Cell Carcinoma
- Stage IVA Thyroid Gland Medullary Carcinoma
- Stage IVB Thyroid Gland Medullary Carcinoma
- Stage IVC Thyroid Gland Medullary Carcinoma
- Thymic Carcinoid Tumor
- VIP-Producing Neuroendocrine Tumor
- Well Differentiated Adrenal Cortex Carcinoma
- Zollinger Ellison Syndrome
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of veliparib (ABT-888) in combination with capecitabine and temozolomide in patients with advanced well-differentiated neuroendocrine tumors.
SECONDARY OBJECTIVES:
2. To determine the safety profile of the combination of capecitabine, temozolomide and veliparib in patients with advanced well-differentiated neuroendocrine tumors (NET).
3. To evaluate the antitumor activity of the combination of capecitabine, temozolomide and veliparib in advanced well-differentiated NET patients
4. To determine progression-free survival (PFS) of the combination of capecitabine, temozolomide, and veliparib in advanced well-differentiated NET patients IV. To evaluate the association between pharmacodynamic biomarkers and response in patients with advanced well-differentiated NET patients.
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pathologically confirmed metastatic unresectable well differentiated (low grade and intermediate grade) neuroendocrine tumors (Ki-67 < 20% and mitotic rate < 2 per 10 high power field) that demonstrate progressive disease (by serial computed tomography [CT] or magnetic resonance imaging [MRI] scans) in past 12 months including
- Carcinoid tumors originating anywhere in the body including the gastrointestinal (GI) tract or bronchial tree or thymus
- Pancreatic neuroendocrine tumors (including functional and non-functional islet cell, insulinomas and glucagonomas)
- Pheochromocytomas
- Gastrinomas (Zollinger-Ellison syndrome)
- Multiple endocrine neoplasia (MEN type I/II),
- Adrenal carcinomas with NET markers by immunohistochemistry (IHC) or serum
- Somatostatinoma
- VIPoma (vasoactive intestinal peptide)
- Merkel cell tumors
- Medullary thyroid carcinoma
- Neuroendocrine tumors of unknown primary site
- Patients must have progressed on octreotide therapy and/or radioactive isotopes linked to octreotide or its congeners if they had a positive octreotide scan; patients who have negative or mildly positive octreotide scans are exempt from this requirement
- Somatostatin analogs can be continued at their tolerated dose in patients with functional symptoms related to underlying disease such as in functional islet cell, insulinomas, glucagonomas etc
- Patients may have received prior chemotherapy for advanced disease including either capecitabine or temozolomide single agent as long as it did not include combination of capecitabine and temozolomide
- Patients must have completed prior (non-excluded) anti-cancer therapy (including surgery or chemotherapy or hepatic embolization/chemoembolization or radioactive isotopes i.e. yttrium 90) at least 4 weeks prior to day 1
- Patients with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intracranial disease and have not had treatment with steroids within 1 week of study enrollment
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Anticipated life expectancy of greater than 3 months
- Patients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure response
- Granulocytes > 1,500/ml
- Platelets > 100,000/ml
- Hemoglobin >= 10 g/dl
- Creatinine < 1.5 x upper limit of normal (ULN) or creatinine clearance >= 50 mL/min/1.73 m^2 for subjects with creatinine levels above institutional normal
- Bilirubin < 1.5 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if liver metastases are present)
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of veliparib, capecitabine and temozolomide administration
- Ability to understand and the willingness to sign a written informed consent document
- Patients must be able to swallow pills
Exclusion Criteria:
- Prior chemotherapy with combination of capecitabine (or 5-flourouracil [5-FU]) "and" temozolomide (or dacarbazine [DTIC]) will be excluded; patients can have had prior therapies up to 3 prior chemotherapy regimens such as streptozocin, anthracyclines, irinotecan, etoposide, or a platinum agent including single agent capecitabine (or 5FU) or temozolomide (or DTIC).
- History of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions)
- Patients who have active or uncontrolled infection or serious medical or psychiatric illness preventing informed consent or on intensive treatment
- Patients with brain metastases are excluded
- Patients with uncontrolled seizures or any neurological conditions resulting in increased risk for seizures are not eligible for study entry
- Patients with documented central nervous system (CNS) ischemia and/or infarction, whether symptomatic or discovered incidentally without clinical symptoms, will be excluded from study participation
- Patients with a history of the arterial or venous thromboembolism within =< 12 months of study entry are not eligible
- Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are excluded from the study
- Patients with another active malignancy within the past five years except for carcinoma in situ of cervix or in situ carcinoma of the bladder or non-melanomatous carcinoma of the skin
- Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities
- Patients who are receiving any other investigational agents
- Major surgical procedure within 4 weeks of treatment
Patients may not have any clinically significant cardiovascular disease including the following:
- Myocardial infarction or ventricular tachyarrhythmia within 6 months
- Prolonged QTc > 480 msec at baseline
- Symptomatic congestive heart failure (CHF) of New York Heart Association (NYHA) functional class >= 3
- Major conduction abnormality (unless a cardiac pacemaker is present)
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with capecitabine or temozolomide or veliparib
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (capecitabine, temozolomide, veliparib)
Capecitabine PO BID on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14.
|
Correlative studies
Correlative studies
Given PO
Given PI
given PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Time Frame: Up to 28 days
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate measured as complete response, partial response or stable disease according to RECIST 1.1 criteria
Time Frame: 56 days (2 courses)
|
56 days (2 courses)
|
Response duration
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Progression Free Survival
Time Frame: From start of treatment to time of progression or death, assessed up to 4 weeks
|
From start of treatment to time of progression or death, assessed up to 4 weeks
|
Overall Survival
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Poly-adenosine diphosphate (ADP)-ribosylated (PAR) level
Time Frame: Baseline to day 15 of course 1
|
Baseline to day 15 of course 1
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jordan Berlin, M.D., Vanderbilt-Ingram Cancer Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Virus Diseases
- Infections
- Neoplasms by Histologic Type
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Disease Attributes
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Genetic Diseases, Inborn
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Intestinal Diseases
- DNA Virus Infections
- Tumor Virus Infections
- Peptic Ulcer
- Duodenal Diseases
- Neoplastic Syndromes, Hereditary
- Pancreatic Diseases
- Paraneoplastic Syndromes
- Adenoma
- Adrenal Gland Diseases
- Polyomavirus Infections
- Neoplasms, Multiple Primary
- Neoplasms, Ductal, Lobular, and Medullary
- Pancreatic Neoplasms
- Adrenal Cortex Neoplasms
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Paraganglioma
- Carcinoma, Islet Cell
- Paraneoplastic Endocrine Syndromes
- Neoplasms
- Carcinoma
- Recurrence
- Thyroid Diseases
- Thyroid Neoplasms
- Carcinoma, Neuroendocrine
- Neuroendocrine Tumors
- Carcinoma, Merkel Cell
- Endocrine Gland Neoplasms
- Carcinoid Tumor
- Adenoma, Islet Cell
- Pheochromocytoma
- Adrenocortical Carcinoma
- Insulinoma
- Gastrinoma
- Glucagonoma
- Somatostatinoma
- Vipoma
- Multiple Endocrine Neoplasia
- Carcinoma, Medullary
- Zollinger-Ellison Syndrome
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type 2a
- Multiple Endocrine Neoplasia Type 2b
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Temozolomide
- Capecitabine
- Veliparib
Other Study ID Numbers
- VICC GI 14134
- NCI-2016-01044 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Merkel Cell Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Merkel Cell Carcinoma | Metastatic Merkel Cell Carcinoma | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Cutaneous Merkel... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)CompletedRecurrent Merkel Cell Carcinoma | Stage III Merkel Cell Carcinoma AJCC v7 | Stage IV Merkel Cell Carcinoma AJCC v7 | Stage IIIA Merkel Cell Carcinoma AJCC v7 | Stage IIIB Merkel Cell Carcinoma AJCC v7United States
-
Melanoma and Skin Cancer Trials LimitedRecruitingNeuroendocrine Tumors | Merkel Cell Carcinoma | Merkel Cell Carcinoma, Stage I | Merkel Cell Carcinoma, Stage II | Merkel Cell Carcinoma, Stage III | Carcinoma Neuroendocrine SkinAustralia, New Zealand
-
University of WashingtonEMD SeronoActive, not recruitingStage III Merkel Cell Carcinoma AJCC v8 | Stage IIIB Merkel Cell Carcinoma AJCC v8 | Stage IIIA Merkel Cell Carcinoma AJCC v8United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
National Cancer Institute (NCI)SuspendedPathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
ImmunityBio, Inc.UnknownStage IIIB Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
University of WashingtonIncyte CorporationRecruitingMerkel Cell Carcinoma | Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedStage IV Merkel Cell Carcinoma AJCC v7 | Merkel Cell Polyomavirus InfectionUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed